We performed a single institution retrospective analysis of 114 patients treated with BU-based pretransplant conditioning regimens. Oral BU was administered to 76 patients (total dose 16 mg/kg or 8 mg/kg) and i.v. BU to 38 others (total dose 12.8 mg/kg or 6.4 mg/kg). Either CY (n ¼ 74) or fludarabine (n ¼ 40) was given in combination with BU. Median age was 35 years in the oral BU group and 48.5 years with i.v. BU (Po0.001). OS and PFS rates at 3-years post HSCT were not different in patients who received either i.v. or oral BU (OS: 41.3 vs 44.0% (P ¼ 0.981); PFS: 52.7 vs 54.7% (P ¼ 0.526), respectively). The i.v. BU, however, was associated with a significantly shorter time to engraftment (13.5 days vs 16 days, respectively; Po0.001). There were no significant differences in survival or 100-day mortality for patients who received either CY or fludarabine, in combination with BU. After adjustment for confounders, multivariate analysis showed that age of transplant (P ¼ 0.002), donor type (sibling or unrelated; P ¼ 0.003), GVHD (Po0.05) and route of administration (P ¼ 0.023) were significant risk factors for OS. The i.v. BU used in an older age group yielded equivalent survival compared with oral BU used in a younger population.
Introduction
Worldwide, over 30 000 hematopoietic SCTs (HSCTs) are performed annually, with the numbers increasing by 10-20% each year. 1, 2 Various pretransplant conditioning regimens have been developed as an alternative to TBI to reduce toxicity, lower cost and facilitate administration. 3 Although BU-based regimens are the most frequently used pretransplant conditioning regimens, they can be administered in many permutations that vary in terms of route of administration, dosage and combination. Each of these factors may significantly affect the outcomes of HSCT.
In the formulation of BU-conditioning regimens, the selection of route of administration is crucial, as oral BU has a narrow therapeutic index due to unpredictable intestinal absorption and erratic hepatic clearance. 4 These factors lead to a more than 10-fold individual variability in pharmacokinetics. 5 Variability in BU concentration has been linked to adverse outcomes, such as development of veno-occlusive disease (VOD) and engraftment failure or disease relapse. 6, 7 The first preparation of i.v. BU was introduced in 1996 and since then, BU-based conditioning regimens using the i.v. preparations have been shown to produce predictable blood levels, lower incidence of VOD and similar immunosuppressive effects. 8 Other factors that influence HSCT outcomes include the types of chemotherapeutic drugs that are used together with BU in the pre-transplant conditioning regimen. Since 1978, the use of BU and CY (BuCy) as a pretransplant conditioning regimen was adopted widely in transplant centers worldwide due to its ease of administration and good efficacy. 9 A major disadvantage of this combination is the increased risk of developing VOD. 10 Recently, an alternative combination of BU and fludarabine (BuFlu) has been used with initial results showing a decrease in treatment-related mortality, allowing BuFlu to be used in an effort to avoid synergistic injury to organs. [11] [12] [13] Many studies in the past have addressed the pharmacokinetics, efficacy and early clinical outcomes of various BUbased conditioning regimens. 8, 14, 15 More recently, studies have individually compared the route of administration (oral or i.v.), the combination (BuCy or BuFlu) and the dosage (high dose or low dose) of BU-based conditioning regimens. [16] [17] [18] However, no reports have evaluated all the above mentioned factors in a single study. Hence, this study was performed to determine, in a single cohort, outcomes for different BU regimens that differ, based on route of administration (oral or i.v.), dosages (high dose or low dose) and combinations (with CY or fludarabine). Survival outcomes, treatment-related mortality and relapse rates were assessed according to each preparative regimen in an effort to determine optimal pretransplant BU-based regimens for allogeneic HSCT in myelogenous malignancies.
Subjects and methods
Patient data were collected under an approved study protocol that had been reviewed by the SingHealth Institutional Review Board. The data was extracted from the Singapore General Hospital (SGH) HSCT registry from the period from January 1999 to December 2009. Risks associated with the treatment protocol were explained to both donors and patients. All patients signed an informed consent before the transplant, in accordance with the SGH guidelines.
Inclusion criteria included patients with AML, ALL, chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS) defined by the World Health Organization (WHO). Patients had to be between 15 and 65 years with normal renal, hepatic and central nervous system function. They also had to be sero-negative for HIV, hepatitis B and hepatitis C.
Study design
The analysis compared patients who had undergone allogeneic HSCT using one of the four BU-based conditioning regimens: oral BuCy; i.v. BuCy; oral BuFlu; i.v. BuFlu. The dose of BU in patients receiving BuCy and BuCy regimens were 8 mg/kg (low-dose oral) or 16 mg/kg (high-dose oral) and 6.4 mg/kg (low-dose i.v.) or 12.8 mg/kg (high-dose i.v.), respectively, followed by i.v. CY (60 mg/kg) over 2 h for 2 consecutive days. Patients on the BuFlu regimens received i.v. fludarabine (30 mg/m 2 ), followed by oral BU (total dosage: 8 mg/kg or 16 mg/kg) or i.v. BU (total dosage 6.4 mg/kg or 12.8 mg/kg), respectively. Targeted BU therapy was not performed for patients included in this study. All doses of BU, CY and fludarabine were calculated using actual body wt if it was less than or equal to ideal body wt, or ideal body wt if it was less than actual body wt.
Upon completion of BU-based pre-HSCT conditioning regimens, patients were given one day of rest before administering the stem cell product. All patients received a combination of either MTX (15-10 mg/m 2 ) and CYA (3 mg/kg), or CYA (3 mg/kg) and mycophenolate mofetil (750 mg BD) or all three agents as prophylaxis against GVHD. Acute and chronic GVHD were assessed clinically and graded using the guidelines of the Consensus Conference. 19, 20 Pre-transplant chemotherapy regimens were given as followed: Patients with AML, CML blast crisis or MDS in transformation received 3 days of idarubicin and 7 days of cytarabine in standard 3 þ 7 induction and 2 þ 7 consolidation regimens, as previously published. 21 Patients with ALL received hyper CVAD(CY, VCR, Doxorubicin, Dexamethasone) chemotherapy treatment. 22 Disease subsets were similar in both i.v. and oral BU groups, and there was no difference in pre-transplant chemotherapy regimens used in i.v. or oral BU groups.
Supportive care
Phenytoin was administered during and until 1 day after BU treatment. Infectious disease prophylaxis strategies used included drugs, such as ciprofloxacin, acyclovir, bactrim and itraconazole. Anti-emetics and recombinant granulocyte CSF were used according to the institutional protocol. Mesna (2-MercaptoEthane sulfonate sodium) was infused for prophylaxis of hemorrhagic cystitis before CY therapy. Blood products were leukocyte depleted and irradiated before transfusion. All patients received either screened or filtered blood products.
Engraftment
The clinical end points consisted of: (1) OS, (2) PFS, (3) incidence of veno-occlusive disease, (4) number of days to engraftment, (5) GVHD, (6) treatment-related mortality and (7) relapse rate.
Initial engraftment was confirmed by peripheral blood film and defined as the first of 3 consecutive days with ANC equal to or more than 0.5 Â 10 9 /L. Initial platelet engraftment was defined as the first of 3 consecutive days with a platelet count of 20 Â 10 9 /L or more, without transfusion support. Failure to engraft by day 30 was considered primary engraftment failure. Secondary graft failure was defined as initial engraftment with documented donorderived hematopoiesis, followed by loss of graft function without recurrent malignancy. Post-transplant donor chimerism was assessed by means of variable non-tandem repeat analysis by PCR.
The criteria for CR before transplantation included absence of circulating blasts, less than 5% marrow blasts, lack of chromosomal abnormalities and peripheral blood evaluation (Hb more than or equal to 11 g/dL untransfused; ANC more than or equal to 1000/mm 3 without myeloid growth factor support and platelet count equal to or more than 100 Â 10 9 /L, without hematopoietic support). For patients with leukemia, remission was defined as the absence of malignant cells in the marrow with normalization of marrow morphology and peripheral blood counts. CR after transplantation was defined using the same criteria except for platelet count, with donor cell engraftment.
OS was calculated from the day of transplantation, with patients alive at the time of last follow-up administratively censored. PFS time was defined by the physician-n-charge of the patient on the basis of blood and BM blast percentage in addition to clinical parameters, such as the presence of extramedullary disease, from day of transplant, with patients alive at the time of last follow-up administratively censored. Relapse and progression of disease were defined by the day of detection using flow cytology, conventional cytogenetic and PCR. Treatment related mortality (TRM) was defined as death due to any cause other than relapse within day 100. Surviving patients in clinical remission were censored at the day of last follow-up.
Organ toxicities were monitored for all patients from day 1 through day 100 post transplant; all patients were evaluated daily by clinicians for adverse events and hematological parameters whereas clinical laboratory values were followed at least once weekly. Clinical diagnosis of VOD was determined based on the clinician's clinical examination and laboratory data. All patients were re-evaluated for VOD, using the criteria of Jones et al. 23 published in 1987.
Post transplant, patients were monitored daily during admission for adverse events and hematological parameters. Other laboratory parameters including renal and liver function were measured twice a week until discharge. Upon discharge to day 100 post HSCT, patients were followed up for regimen-related toxicities, engraftment quality and relapse. Subsequently, disease status and survival of post-HSCT patients were tracked every 3 months. Data collection was standardized by the use of case reporting forms and established guidelines. An independent experienced clinical research associate collected and verified the accuracy of the data.
Statistics
Results were analyzed according to the information available from the SGH HSCT registry from January 1999 to December 2009. The day of the stem cell infusion in HSCT was regarded as day 0.
The primary endpoints were PFS and OS at 3-years post transplant. Secondary endpoints included days to engraftment, acute and chronic GVHD, incidence of VOD, TRM censored at 100 days post transplantation and relapse rate. The Fisher exact test was used for comparisons of variables (days to engraftment, regimen-related organ toxicities, acute and chronic GVHD, and incidences of VOD). Survival curves were estimated using the Kaplan-Meier method and compared for differences among BU combinations and doses, using the log-rank test. Cox proportional hazards regression analysis was used to identify demographic variables and patient characteristics predictive of PFS and OS. Confidence intervals for hazard ratios were calculated using Wald's method. All tests were two-sided and considered statistically significant for Po0.05. The statistical data were obtained using the SAS software package version 9.2 (SAS Institute Inc, Cary, NC, USA).
Results

Patients and disease characteristics
A total of 114 patients received BU-based chemotherapeutic regimens for HSCT, of which 76 (44 men and 32 women) were administered oral BU and 38 (11 men and 27 women) were given i.v. BU (Table 1 ). In all, 58 patients received oral BU with CY, 16 patients received i.v. BU with CY, 18 patients received oral BU with fludarabine and 22 patients received i.v. BU with fludarabine. The median age of patients was 35 years in the oral BU group and 48.5 years in the i.v. BU group. Diagnoses included AML (n ¼ 66), ALL (n ¼ 7), CML (n ¼ 27) and MDS (n ¼ 14). Cytogenetics for myelogenous malignancies (AML and MDS) were further analyzed as high, intermediate and lowrisk groups and no significant differences were found in these subgroups between i.v. and oral BU.
There were no significant differences in the sex, ethnicity, body mass index (BMI) and infectious status of the patients Transplantation outcomes Engraftment. All 114 patients had sustained engraftment. The patients in the oral BU group attained engraftment after a median of 16 days (range 9-28 days), whereas the patients in the i.v. BU group attained engraftment after a median of 13.5 days (range 7-35 days). The i.v. BU group required a shorter time to achieve engraftment (Po0.001).
Patients who received BM (n ¼ 46) attained engraftment in an average of 18 days, whereas those who received PBSCs (n ¼ 68) attained engraftment in 13.6 days, which was statistically significant (Po0.05). The higher proportion of patients receiving PBSCs and differences between related and unrelated donors could be potential confounders to the days to engraftment in the i.v. BU group. There was no late post-transplant graft failure in any patient in either group.
GVHD
Acute GVHD. Acute GVHD was documented in 77 (68%) patients, with 55 patients in the oral BU group and 22 patients in the i.v. BU group. In the oral BU group, 31 (42%) had grade I to II acute GVHD and 24 (32%) had grade III to IV GVHD. In the i.v. BU group, 15 (39%) experienced grade I to II acute GVHD and 7 (18%) had grade III to IV GVHD. A significant number of patients with grade III to IV received BM infusion as compared with those who received PBSCs (P ¼ 0.045).
Only one patient in the oral BU group died of GVHD before HSCT day 100, but beyond HSCT day 100, four patients in the oral BU group and none in the i.v. BU group died of GVHD. The percentage of patients with acute GVHD of grade III to IV was significantly lower in the i.v. BU group. Chronic GVHD. Beyond day 100, there were 97 (85%) survivals. In all, 14 (22%) patients developed limited GVHD and 12 (19%) patients developed extensive GVHD in the oral BU group. A different trend was observed in the i.v. BU group whereby three (9.4%) patients developed limited GVHD and four (13%) patients developed extensive GVHD. There were no significant differences in the development of chronic GVHD between the oral and i.v. BU group. Interestingly, there was also no difference in chronic GVHD between patients who received either BM or peripheral blood-BM transfusion, which is different from the results of other studies in Western populations, and this could be, among other reasons, due to the different ethnicity of our patients (predominantly Chinese).
Hepatic VOD. Although i.v. BU had been reported to result in a lower incidence of VOD, 8 our results show that there was no significant difference between oral and i.v. BU administration in the development of VOD, 12.5% (n ¼ 9) vs 18.4% (n ¼ 7), respectively (P ¼ 0.15). The incidence of fatality attributed to VOD in the oral BU group was 3% and in the i.v. BU group was 14% (P40.05). The results may be due to differences in patient selection between the two groups as discussed later.
Treatment related mortality. There were a total of 17 regimen-related mortalities during the first 100 days post HSCT. Deaths after 100 days were primarily due to disease relapse and 100-day TRM was experienced by 14.8% (n ¼ 11) and 15.8% (n ¼ 6) in the oral and i.v. BU groups, respectively. Both infections and VOD were common causes of TRM in both the oral and i.v. BU groups, whereas GVHD was causative only in the oral BU group. In the oral BU group, the main causes were GVHD, infection and VOD. In the i.v. BU group, the main causes of TRM were infections and VOD. No significant difference was noted for mortality rates at 100 days post transplant.
Relapse rate A total of 40 (37%) patients experienced relapse of malignancy. This occurred in 25 (35%) patients in the oral BU group and 15 (39%) patients in the i.v. BU group. There was no significant difference in the relapse rates between the two groups.
Survival
Oral BU as compared with i.v. BU. Results for univariate analysis (Table 2) are presented, with the main focus on the results of multivariate analysis, which adjust for confounders (Table 3) . On univariate analysis, the variables that were found to contribute to decrease the OS included age at transplant (P ¼ 0.040) and acute GVHD stage III-IV (P ¼ 0.004; Table 2 ). With further analysis and accounting for confounder effects, the multivariate analysis showed that age at transplant (P ¼ 0.002), donor type (sibling or unrelated; P ¼ 0.003), acute and chronic GVHD (Po0.05) and route of administration (P ¼ 0.023) were significant risk factors for OS (Table 3 ).
In the oral BU group, the median OS was 17.4 months, as compared with 17.8 months in the i.v. BU group. The estimated 3-year OS rate was 44.0% in the oral BU group and 41.3% in the i.v. BU group (Figure 1) . The OS was not significantly different in the two groups (P ¼ 0.981). PFS rates were similar in both oral and i.v. BU groups with a 3-year PFS rate of 36.4 vs 35.6% (P ¼ 0.689), as shown in Figure 2 . On univariate analysis and multivariate analysis, none of the variables were shown to have an effect on PFS (Tables 2 and 3 ).
Optimizing BU-based pre-HSCT conditioning regimens AM Wong et al Table 2 Univariate analysis of OS and PFS
OS PFS
Hazard ratio 
Confidence interval
P-value
BU and CY (BuCy) vs BU and fludarabine (BuFlu).
A total of 74 patients received conditioning regimens consisting of BuCy, whereas 40 patients received BuFlu. The OS rates at 3-year for patients receiving CY or fludarabine as part of their conditioning regimen were 46.0 and 38.6%, respectively (P ¼ 0.259). The PFS rates at 3-year were 38.6% vs 17.3% (P ¼ 0.200) in the BuCy and BuFlu groups, respectively (Figures 3 and 4) .
High-dose BU as compared with low-dose BU High dose (total dosage 16 mg/kg) BU (n ¼ 80) was compared against low dose (total dosage 8 mg/kg) BU (n ¼ 34). The OS rates at 3-year were 45.3% for high dose and 42.4% for low dose (P ¼ 0.960). The PFS rates at 3-year were 37.2% for high dose and 46.3% for low dose (P ¼ 0.718).
Control group
We also analyzed OS and PFS for patients who received 
Discussion
In this study, we found that i.v. BU used in an older age group produced similar OS and PFS at 3-years post transplantation as compared with oral BU used in a younger patient group. The differences in BU dosages and combinations with either fludarabine or CY did not produce any significant differences in OS and PFS rates. Even though our results showed that there were no significant differences in OS and PFS between patients receiving i.v. or oral BU, it must be noted that the median age of patients receiving i.v. BU was significantly older than those who were given oral BU (median: 48.5 vs 35.0 years). Hence, to have a similar OS and PFS, rate for the i.v. and oral BU group suggests that an i.v. BU-based conditioning regimen may be better tolerated despite older age. In addition, patients receiving i.v. BU took a significantly shorter duration of time to attain engraftment as compared with the oral BU group (13.5 days vs 16 days, respectively), though it did not translate to differences in the OS and PFS rates. However, due to a higher proportion of patients receiving PBSCs in the i.v. BU group, it could represent a potential confounder to the analysis of days to engraftments. The relapse rates were also comparable in the i.v. and oral BU group (39 vs 35%, respectively). There were no differences noted for OS and PFS rates between the high-and low-dose BU groups, which could be affected by factors such as patient demographics and combination of BU-based regimens.
Oral BU hepatotoxicity has been recognized to be a dosedependent effect, resulting from crystallization of BU in the hepatocytes at high exposure levels. In addition, high BU levels are documented to cause acute chemical hepatitis by depleting glutathione in hepatocytes, and, probably, predisposing to VOD. 17 Hence, i.v. BU was developed to counter the first pass effect of oral leading to much less variability in the pharmacokinetic profile and a decrease in the incidence and severity of VOD. Our data however, did not show a significant difference between the development of VOD in the oral and i.v. BU group and also the mortality incidence caused by VOD. Previous data seems to suggest that that i.v. (0.8 mg/kg) BU is comparable to oral (1 mg/kg) BU dosage. 17 However, Slattery 24 noted in response that the comparison had failed to account for the differences in BU area under the plasma concentration time curve. The mean area under the curve (AUC) for i.v. (0.8 mg/kg) BU was 1167 mM.min, whereas the mean AUC for oral (1.0 mg/kg) BU was found to be 1350-1400 mM.min in adults. Because of the low therapeutic window for BU, the 18% difference in area under the curve may explain why oral BU seemed to be associated with a higher incidence of VOD and more severe morbidities vs the i.v. form. In addition, based on the principles of mass balance and clearance, the differences in AUC between i.v. and oral BU only translates to a slight difference in peak concentrations experienced by the liver. This may partially explain the results of our study, where no significant differences were found in the primary outcomes when comparing i.v. vs oral BU. Recently, McCune and Holmberg 25 published a review article that recognized that there are only slight interpatient variability between i.v. and oral BU concentration, which further substantiates our study's result, showing no differences in primary outcomes between the two groups.
Other possible reasons for these observations could be the different sample sizes and duration of patient followup, as well as the predominantly Asian population in our present study, who are known to have different genetically determined metabolic capacities that may affect the pharmacokinetics and pharmacodynamics of BU. Another possible reason why a difference was not seen in the incidence of VOD between the i.v. and oral BU conditioning regimens could be because patients included in our study were all sero-negative for hepatitis.
Secondary outcome measures, such as acute GVHD, chronic GVHD and TRM were also similar in the oral and i.v. BU group. Even though development of grade III to IV aGVHD were noted to be significantly higher in the i.v. BU group, the differences in GVHD prophylactic regimens and donor-stem cell types could have contributed to the observed difference. Further analysis after adjustment for confounders indicated that the development of acute and chronic GVHD, especially of the higher grades were associated with a decrease in the OS rates. Hence, GVHD development could be a predictor of poorer prognosis due to further damage to organ functions or an increased risk of infection secondary to GVHD. 26 One of the major concerns of TRM resulting from hepatic VOD in BU-based conditioning regimens is the use of the additive cytotoxicities of two alkylators, such as CY and BU. Recently, a combination of BuFlu has been used as a preparative regimen for allogeneic HSCT. Although fludarabine is a potent immunosuppressant, it was not found to be associated with BU type toxicities, as it does not deplete glutathione stores. 13, 27 Studies have shown that regimen-related toxicity maybe reduced by using BuFlu instead of BuCy. 25 In contrast to previous studies, we found no significant differences in the OS rates between BuCy and BuFlu regimens although BuFlu regimens resulted in significantly shorter PFS durations. This could be due to differences in patient selection in the two populations. Previous studies in patients receiving BuCy and BuFlu regimens showed similar PFS and relapse rates, which could have been due to the shorter follow-up period for patients compared with the present study (1 year vs 3 years). 16 In summary, the BuFlu regimen may be advantageous in terms of minimizing early regimen-related toxicity as compared with BuCy regimen, 11 but one must take into consideration the possibility of lower PFS rates, as obtained in our study.
The most notable limitation of this study was that nonrandomized retrospective data were used and that the duration of i.v. BU administration was significantly shorter than the oral BU. Therefore, additional confounding factors related to patient demographics could have contributed to the results obtained. We tried adjusting for multiple unbalanced factors in our two groups with multivariate analysis and used a control group (CyTBI) to show that time period, which could reflect differences in supportive care, between i.v. and oral BU use was not a confounding factor in this study. A future study with more comparable patient characteristics should be done to exclude age as a confounding factor. However, this could not be done in the present study as retrospective data was used. Also, because of the follow-up period for patients who received i.v. BU was shorter as compared with oral BU, the long-term side effects and efficacy of i.v. BU-based conditioning regimens could not be studied adequately. Future studies could also investigate the pharmacokinetic profiles of oral and i.v. BU in the Asian population to determine if differences in exposure levels of the drug that may affect response, as well as toxicity profiles in patients undergoing HSCT, with BU-based regimens.
In summary, although neither the differences in drug combination nor the BU dosage made a significant impact on survival status, i.v. BU used in an older age group produced equivalent results in terms of survival compared with oral BU used in a younger population. In previous studies, i.v. BU was shown to offer a lower dose-to-dose variability in pharmacokinetics, as compared with the oral route;
28 a more precise BU dosage will be beneficial to patients of extreme ages whereby inter-patient variability in plasma BU concentration is higher. 29 Future pharmacokinetic studies that tailor oral or i.v. BU dosages to individual needs could be important.
